Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology · Testicular Seminoma

Validation & Orientation: What is a Testicular Seminoma?

At a Glance

Testicular seminoma is a slow-growing, highly curable type of germ cell tumor with survival rates up to 99% for early stages. Because it is highly responsive to treatment, patients usually have time to bank sperm for fertility preservation before having surgery to remove the testicle.

Hearing the word “cancer” often triggers an immediate “fight or flight” response, but it is important to pause and take a breath. If you have been diagnosed with testicular seminoma, you are facing one of the most curable forms of cancer known to medicine [1][2].

Testicular cancer is the most common solid tumor in men between the ages of 20 and 40 [3][4]. While the diagnosis is serious, the outlook is exceptionally positive. For men with early-stage (Stage I) seminoma, the survival rate is approximately 99% [5]. Even when the cancer has spread to other parts of the body (Stage II or III), survival remains very high, at around 85%, thanks to modern treatment regimens [5][6].

Understanding Your Diagnosis

Seminoma is a type of germ cell tumor—a cancer that begins in the cells that eventually develop into sperm [7][8]. These tumors typically follow a predictable path and are very sensitive to treatment.

Medical teams divide testicular cancers into two main categories:

  • Seminomas: These usually grow more slowly and are more likely to stay confined to the testicle for longer periods [9][10]. They are highly responsive to both radiation and chemotherapy [11][12].
  • Non-seminomas: These tend to grow more quickly and may spread earlier than seminomas [13][9].

Where It Starts: GCNIS

The biological “seed” of most testicular cancers is a condition called Germ Cell Neoplasia In Situ (GCNIS) [7][14]. Think of GCNIS as a “pre-invasive” state where some germ cells failed to mature correctly before you were even born [7][8]. These cells can remain dormant for decades before eventually developing into an active tumor like a seminoma [15][16].

Taking a Productive Pause

Because seminomas generally grow slowly, there is usually time to take a brief, strategic pause before starting treatment [9]. One of the most important things you can do during this time is address fertility preservation [17][18].

Testicular cancer and its treatments can sometimes affect your ability to father children in the future [18][19]. Sperm cryopreservation (sperm banking) is the standard recommendation for all patients [17][20]. Taking a few days to bank sperm before your surgery is safe and ensures that your options for a future family are protected [17][18].

Why You Can Be Hopeful

The “gold standard” of success in oncology is a cancer that is highly sensitive to treatment even if it spreads. Seminoma is exactly that. Whether your treatment plan involves surgery (called an orchiectomy), active surveillance (careful monitoring with scans and blood tests), or additional therapy, the goal is not just management, but a complete cure [1][21][22].

Your medical team’s job is to guide you through these steps with precision. Your job right now is to gather information, preserve your fertility if that is important to you, and know that the odds are overwhelmingly in your favor.

Common questions in this guide

What is a testicular seminoma?
A testicular seminoma is a type of germ cell tumor that begins in the cells that eventually develop into sperm. It usually grows slowly and is highly curable, often responding very well to treatments like surgery, radiation, and chemotherapy.
What is the survival rate for testicular seminoma?
The survival rate for early-stage testicular seminoma is approximately 99%. Even if the cancer has spread to other parts of the body, the survival rate remains very high at around 85% thanks to modern treatment regimens.
Should I bank sperm before testicular cancer surgery?
Yes, sperm cryopreservation is the standard recommendation for all patients before surgery. Because testicular cancer treatments can affect your ability to father children, taking a few days to bank sperm protects your future fertility options.
What is the difference between a seminoma and a non-seminoma?
Seminomas generally grow more slowly and are more likely to stay confined to the testicle for longer periods. Non-seminomas tend to grow more quickly and may spread to other parts of the body earlier.
What is Germ Cell Neoplasia In Situ (GCNIS)?
GCNIS stands for Germ Cell Neoplasia In Situ, which is a pre-invasive state where germ cells fail to mature correctly. These dormant cells are considered the starting point for most testicular cancers and can eventually develop into active tumors like seminomas.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor a 'pure' seminoma, or is there any non-seminomatous component suspected?
  2. 2.What are my current tumor marker levels (AFP, hCG, and LDH)?
  3. 3.Based on the size and location of the tumor, do I have a high risk of the cancer coming back?
  4. 4.What is the recommended timeline for my surgery, and is there time to complete sperm banking first?
  5. 5.If I choose active surveillance after surgery, how often will I need scans and blood work?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer.

    Kamran SC, Seisen T, Markt SC, et al.

    European urology 2018; (73(2)):262-270 doi:10.1016/j.eururo.2017.06.013.

    PMID: 28687143
  2. 2

    Management of stage I testicular cancer.

    Padayachee J, Clark R, Warde P, Hamilton RJ

    Current opinion in urology 2022; (32(1)):17-23 doi:10.1097/MOU.0000000000000942.

    PMID: 34772865
  3. 3

    Global patterns in testicular cancer incidence and mortality in 2020.

    Znaor A, Skakkebaek NE, Rajpert-De Meyts E, et al.

    International journal of cancer 2022; (151(5)):692-698 doi:10.1002/ijc.33999.

    PMID: 35277970
  4. 4

    Molecular characteristics of testicular germ cell tumors: pathogenesis and mechanisms of therapy resistance.

    Al-Obaidy KI, Chovanec M, Cheng L

    Expert review of anticancer therapy 2020; (20(2)):75-79 doi:10.1080/14737140.2020.1717337.

    PMID: 31951790
  5. 5

    [CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].

    Durand X, Fléchon A, Murez T, et al.

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 2016; (27 Suppl 1()):S147-S165 doi:10.1016/S1166-7087(16)30706-0.

    PMID: 27846929
  6. 6

    Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis.

    Li H, Zhu C, Wu J, et al.

    International urology and nephrology 2021; (53(3)):471-477 doi:10.1007/s11255-020-02659-9.

    PMID: 33052518
  7. 7

    Activin A target genes are differentially expressed between normal and neoplastic adult human testes: clues to gonocyte fate choice.

    Szarek M, Bergmann M, Konrad L, et al.

    Andrology 2019; (7(1)):31-41 doi:10.1111/andr.12553.

    PMID: 30315637
  8. 8

    Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.

    Litchfield K, Levy M, Orlando G, et al.

    Nature genetics 2017; (49(7)):1133-1140 doi:10.1038/ng.3896.

    PMID: 28604728
  9. 9

    Imaging of Metastatic Germ Cell Tumors in Male Patients From Initial Diagnosis to Treatment-Related Toxicities: A Primer for Radiologists.

    Wood MJ, Thomas R, Howard SA, Braschi-Amirfarzan M

    AJR. American journal of roentgenology 2020; (214(1)):24-33 doi:10.2214/AJR.19.21623.

    PMID: 31573853
  10. 10

    Seminoma component of mixed testicular germ cell tumor shows a higher incidence of loss of heterozygosity than pure-type seminoma.

    Miyai K, Ito K, Nakanishi K, Tsuda H

    Human pathology 2019; (84()):71-80 doi:10.1016/j.humpath.2018.09.007.

    PMID: 30266250
  11. 11

    Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls.

    Morra S, Piccinelli ML, Cano Garcia C, et al.

    International urology and nephrology 2023; (55(12)):3119-3128 doi:10.1007/s11255-023-03763-2.

    PMID: 37640983
  12. 12

    Current Insights into Interethnic Variability in Testicular Cancers: Population Pharmacogenetics, Clinical Trials, Genetic Basis of Chemotherapy- Induced Toxicities and Molecular Signal Transduction.

    Vasistha A, Kothari R, Mishra A, et al.

    Current topics in medicinal chemistry 2020; (20(20)):1824-1838 doi:10.2174/1568026620666200618112205.

    PMID: 32552648
  13. 13

    Modern Management of Testicular Cancer.

    Chen J, Daneshmand S

    Cancer treatment and research 2018; (175()):273-308 doi:10.1007/978-3-319-93339-9_13.

    PMID: 30168127
  14. 14

    An introduction to the WHO 5th edition 2022 classification of testicular tumours.

    Berney DM, Cree I, Rao V, et al.

    Histopathology 2022; (81(4)):459-466 doi:10.1111/his.14675.

    PMID: 35502823
  15. 15

    Molecular and epigenetic pathogenesis of germ cell tumors.

    Müller MR, Skowron MA, Albers P, Nettersheim D

    Asian journal of urology 2021; (8(2)):144-154 doi:10.1016/j.ajur.2020.05.009.

    PMID: 33996469
  16. 16

    Integrated Molecular Characterization of Testicular Germ Cell Tumors.

    Shen H, Shih J, Hollern DP, et al.

    Cell reports 2018; (23(11)):3392-3406 doi:10.1016/j.celrep.2018.05.039.

    PMID: 29898407
  17. 17

    Testicular Cancer Survivorship and Fertility Preservation.

    Tverye A, Nangia A, Fantus RJ

    The Urologic clinics of North America 2024; (51(3)):429-438 doi:10.1016/j.ucl.2024.03.011.

    PMID: 38925745
  18. 18

    Frequent azoospermia in patients with testicular germ cell cancer and a history of cryptorchidism: a report of nine cases and review of the literature.

    Hagiuda J, Nakagawa K, Oya M

    Systems biology in reproductive medicine 2021; (67(3)):189-192 doi:10.1080/19396368.2020.1867666.

    PMID: 33630670
  19. 19

    Reduced semen quality in patients with testicular cancer seminoma is associated with alterations in the expression of sperm proteins.

    Dias TR, Agarwal A, Pushparaj PN, et al.

    Asian journal of andrology 2020; (22(1)):88-93 doi:10.4103/aja.aja_17_19.

    PMID: 31006710
  20. 20

    Semen parameters in testicular tumor patients before orchiectomy: What is the impact of testicular tumor stage and histology?

    Mendes G, Teixeira B, Madanelo M, et al.

    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2024; (96(1)):12238 doi:10.4081/aiua.2024.12238.

    PMID: 38389451
  21. 21

    Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).

    Bastos DA, Gongora ABL, Dzik C, et al.

    Clinical genitourinary cancer 2023; (21(3)):e104-e113 doi:10.1016/j.clgc.2022.11.004.

    PMID: 36509612
  22. 22

    Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients.

    John A, Baumgart A, Worst T, Heinzelbecker J

    Urologia internationalis 2018; (100(3)):279-287 doi:10.1159/000486343.

    PMID: 29514158

This page provides educational information about testicular seminoma and fertility preservation. It does not replace professional medical advice. Always consult your urologist or oncologist regarding your specific diagnosis, tumor markers, and treatment plan.

Get notified when new evidence is published on Testicular seminomatous germ cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.